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MIC distribution of clinical APEC strains
The MIC’s of 120 strains were determined
(commercial gradient strip test, Etest). Forty-
one percent of the strains were non-wild type
(edipemiological cut-off, ECOFF: 125 µg/mL),
21% were clinically intermediate and 11% were
clinically resistant (MIC ≥ 2 µg/mL).
OBJECTIVES
PRELIMINARY RESULTS FUTURE PERSPECTIVES
INTRODUCTION
Colibacillosis is one of the leading causes of disease-
related economic loss in the poultry sector
Fluoroquinolones are frequently used antimicrobials
for the treatment of avian pathogenic Escherichia coli
(APEC) infections
However, development and selection of resistance to
these antimicrobial drugs is an increasing problem
Establish an optimized dosage regimen for ENRO for
the effective treatment of colibacillosis in broilers using
pharmacokinetic/pharmacodynamic (PK/PD) modeling
and Monte Carlo simulation (MCS)
Assess the prevalence of resistance against
enrofloxacin (ENRO) in clinical APEC isolates
MATERIALS AND METHODS
Clinical APEC 
isolates
In vivo animal trials
• IV(n=8) / PO(n=8) administration:
rich sampling, 15 samples over
24h per individual
• PO administration (n=120):
sparse sampling, 5 samples
over 32h per individual
• Drinking water administration
for 3 consecutive days (n=75
divided over 5 major groups
receiving different dosages):
sparse sampling, 6 samples over
79h per individual
LC – MS/MS 
analysis
MIC determination MIC distribution
Population PK analysis 
(Phoenix® 8.1)
Time-kill experiments
PK/PD parameter
AUC/MIC
PK parameter distribution
 Cl
 Vd
 Secondary parameters
MCS
Spaghetti plot of 75 concentration-
time profiles (drinking water) 
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Spaghetti plot of 120 concentration-time 
profiles (after a single oral bolus, 10 mg/kg BW) 
 Time kill curves (TKC) data analysis
 Simultaneous (pop)PK modeling of
PK datasets (IV, PO, drinking water)
 Perform MCS using the MIC
distribution and the PK/PD-
parameters
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Select the dose that achieves
the selected PK/PD index for
90% of the target population
(PTA of 90%)
Different doses:
- Yellow: 20 mg/kg BW
- Purple: 15 mg/kg BW
- Red: 10 mg/kg BW (licensed)
- Green: 5 mg/kg BW
- Blue: 2.5 mg/kg BW
The estimated population PK
parameter values [95% CI] were:
- Vd: 5491 mL/kg [5428 ; 5555]
- Cl: 538 mL/kg/h [532 ; 544]
- Ka: 0.618 h
-1 [0.61 ; 0.63]
- F: 97.84% [97.68 ; 97.98]
